Home > Hot Topics > NVO

NVO

Laying Out Our Strategy for the Second Half of 2012

The rest of the year will be driven in large part by four factors. See what they are -- and which five stocks are in a strong position to do well. More 

Earnings Season Brings Joy or Sorrow

Earnings season is difficult for everyone, as winners tend to get big stock bumps, while losers tend to go the other way: down. Hang on! More 

Here Comes a Bidding War for Amylin

Approval of its diabetes drug has Big Pharma banging on its door, with Bristol-Myers Squibb already said to have offered $3.5 billion, or $22 per share. More 

9 Pharma Buys for a Healthy Portfolio

Their dividends are attractive, and some drugmakers have made great progress in refilling their pipelines. More 

10 Pharma Blue Chips to Buy

There are a number of great companies in pharma if you know where to look. More 

3 Stocks Making Huge Leaps After Strong Earnings Reports

These three names are riding high after stellar earnings reports. More 

10 Game-Changing Health Care Stocks to Buy

These 10 diverse stocks are likely to improve their earnings and stock prices in 2012. Take a look. More 

More NVO
Previous Page